4.6 Review

The Pharmacogenetics Research Network: From SNP discovery to clinical drug response

Journal

CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 81, Issue 3, Pages 328-345

Publisher

WILEY
DOI: 10.1038/sj.clpt.6100087

Keywords

-

Funding

  1. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U19HL069757, U01HL069757, U01HL065899, U01HL065962, U19HL065962] Funding Source: NIH RePORTER
  2. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U19GM061388, U01GM061373, R24GM061374, U01GM061374, U01GM074492, U19GM061390, U01GM061388, U01GM061390, U01GM074518, U01GM061393, U01GM063340] Funding Source: NIH RePORTER
  3. NATIONAL INSTITUTE ON DRUG ABUSE [U01DA020830] Funding Source: NIH RePORTER

Ask authors/readers for more resources

The NIH Pharmacogenetics Research Network (PGRN) is a collaborative group of investigators with a wide range of research interests, but all attempting to correlate drug response with genetic variation. Several research groups concentrate on drugs used to treat specific medical disorders (asthma, depression, cardiovascular disease, addiction of nicotine, and cancer), whereas others are focused on specific groups of proteins that interact with drugs (membrane transporters and phase 11 drug-metabolizing enzymes). The diverse scientific information is stored and annotated in a publicly accessible knowledge base, the Pharmacogenetics and Pharmacogenomics Knowledge base (PharmGKB). This report highlights selected achievements and scientific approaches as well as hypotheses about future directions of each of the groups within the PGRN. Seven major topics are included: informatics (PharmGKB), cardiovascular, pulmonary, addiction, cancer, transport, and metabolism.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available